This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales

Zentalis Pharmaceuticals Inc. (NASDAQ: ZNTL ) received a bullish initiation from William Blair, which sees a potential blockbuster opportunity for the biotech company's lead cancer drug, azenosertib. William Blair analyst Matt Phipps initiated coverage of Zentalis with an Outperform rating. The firm's thesis centers on azenosertib, an oral WEE1 inhibitor being developed for Cyclin E1-positive platinum-resistant ovarian cancer, or PROC.

DENALI Data Could Unlock Accelerated Approval William Blair identified the registration-enabling Phase 2 DENALI trial as Zentalis' most important near-term catalyst. Top-line results from DENALI Part 2 are expected in the first half of 2027. William Blair said positive results could support an accelerated approval filing and give azenosertib a first-mover advantage in Cyclin E1-positive PROC. That biomarker-defined group represents roughly half of PROC patients.

The firm expects azenosertib could deliver a response rate above 30% and response durability of more than six months in DENALI Part 2. 3 months. The Phase 3 ASPENOVA trial is designed to confirm the drug's benefit and potentially support full approval. 3 Billion Peak Sales William Blair estimates a potential 2028 launch for azenosertib.

23 per Zentalis share, including net cash. S. penetration of 50% in 2033, monthly pricing of $38,000 and a median treatment duration of six months. S.

3 billion worldwide. 's (NYSE: ABBV ) Elahere as evidence of demand for biomarker-directed treatments in PROC. The firm expects Elahere to exceed $850 million in sales in 2026. See More: Top Value Stocks Improved Tolerability Could Differentiate Azenosertib A key part of William Blair's bullish thesis is azenosertib's selectivity for WEE1 compared with AstraZeneca PLC's (NYSE: AZN ) discontinued WEE1 inhibitor adavosertib.

The firm said azenosertib's greater kinase selectivity, intermittent dosing and improved supportive care have reduced the severity of gastrointestinal and myelosuppression-related side effects. William Blair believes that could help patients remain on treatment longer and improve the durability of benefit. Zentalis selected a 400-milligram daily, five-days-on and two-days-off regimen for DENALI Part 2. William Blair noted that this dose produced a higher response rate than the 300-milligram regimen with a comparable safety profile.

Discontinuations due to adverse events were also roughly half the rate seen in DENALI Part 1b. Clinical, Competition And Funding Risks Remain The opportunity carries significant risks. DENALI Part 2 and ASPENOVA have yet to confirm earlier efficacy and safety findings. William Blair said weaker-than-expected DENALI response rates could jeopardize the accelerated approval pathway and potentially push an approval decision toward the ASPENOVA timeline.

Competition is also increasing. Incyte Corporation (NASDAQ: INCY ) is developing the CDK2 inhibitor INCB123667 in Cyclin E1-positive PROC, while several antibody-drug conjugates are targeting the broader ovarian cancer market. 6 million in cash and marketable securities as of June 30. Including proceeds from an August public offering, management expects its cash runway to extend into the first half of 2028.

William Blair cautioned that the company will likely need additional capital to fund development and potential commercialization. 06 at the time of publication on Wednesday, according to Pro data. Image via Shutterstock Read Also: S&P 500 Gains, Crude Falls Ahead Of Fed's Expected First Hike Since 2023: Stock Market Today